Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

ICONSIAM Showcases Thai Culture with ICONSIAM THAICONIC LOY KRATHONG Festival, Strengthening Thailand’s Global Standing

This year’s Loy Krathong event at ICONSIAM celebrates Thai cultural heritage, promotes sustainability, and shines a global spotlight on Thai cultureBANGKOK, THAILAND - Media OutReach ...

ASVDA Startup Ecosystem Forum at InnoVEX 2019 to Create a New stage for Innovation, Entrepreneurship and International Connections

TAIPEI, TAIWAN - Media OutReach - 4 June 2019 - The 2019 InnoVEX took place at Taipei, Taiwan from 29th to 31st May 2019 organized by the Taipei Computer Association (TCA) and TAIT...

Airple Launches New Tech-Driven Platform to Revolutionise Aircon Servicing in Singapore

SINGAPORE - Media OutReach Newswire - 26 November 2024 -On October 4, 2024, Airple, a leader in air conditioning installation, repair, and aircon servicing, launched its innovative new webs...

St. Kitts and Nevis Moves Up Global Passport Ranking Again

BASSETERRE, Saint Kitts and Nevis, April 18, 2020 /PRNewswire-AsiaNet/ -- St. Kitts and Nevis's passport has been ranked top of all Caribbean countries with citizenship-by-investment program...

66 Nobel Laureates Urge India and Pakistan to Defuse Tension

NEW DELHI, March 4, 2019 /PRNewswire-Asianet/-- Under the aegis of the Laureates and Leaders for Children platform, Kailash Satyarthi Children's Foundation, founded by Nobel Peace Laureate M...

Green SM Signs IDR 600 Billion Investment Loan Agreement With BCA

JAKARTA, INDONESIA - Media OutReach Newswire - 3 April 2026 – Green SM Indonesia and Bank Central Asia (BCA) today announced the signing of a five-year investment loan agreement with ...

Spritzer Natural Mineral Water Passes Test for Plastics Contaminants

KUALA LUMPUR, Apr 14, 2021 - (ACN Newswire) - Spritzer Malaysia (Spritzer), Malaysia's best-selling natural mineral water, has released the results of an analysis conducted by a reputable i...

VinFast secures top market position in Vietnam

HANOI, VIETNAM - Media OutReach Newswire - 12 November 2024 – VinFast announced it has delivered more than 11,000 electric vehicles (EVs) to domestic customers in October, bringing i...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastCrackStreamscialis 20 mg fiyathttps://elektroniksigarakeyfi.net/marka/voopoo/taraftarium24taraftarium24taraftarium24